Phenotype and genotype analyses of Chinese patients with autosomal dominant mental retardation type 5 caused by SYNGAP1 gene mutations

Yanxin Wang; Yuqiang Lv; Zilong Li; Min Gao; Xiaomeng Yang; Yue Li; Jianguo Shi; Zaifen Gao; Yi Liu; Zhongtao Gai

doi:10.3389/fgene.2022.957915

Phenotype and genotype analyses of Chinese patients with autosomal dominant mental retardation type 5 caused by SYNGAP1 gene mutations

Front Genet. 2022 Dec 13:13:957915. doi: 10.3389/fgene.2022.957915. eCollection 2022.

Authors

Yanxin Wang¹, Yuqiang Lv^{2

3}, Zilong Li^{2

3}, Min Gao^{2

3}, Xiaomeng Yang^{2

3}, Yue Li^{2

3}, Jianguo Shi^{4

3}, Zaifen Gao^{4

3}, Yi Liu^{2

3}, Zhongtao Gai^{2

4

3}

Affiliations

¹ Department of Pediatrics, Children's Hospital Affiliated to Shandong University, Ji'nan, China.
² Pediatric Research Institute, Children's Hospital Affiliated to Shandong University, Ji'nan, China.
³ Shandong Provincial Clinical Research Center for Children's Health and Disease, Ji'nan, China.
⁴ Epilepsy Center, Children's Hospital Affiliated to Shandong University, Ji'nan, China.

Abstract

Background: Autosomal dominant mental retardation type 5 (MRD5), a rare neurodevelopmental disorder (NDD) characterized by intellectual disability (ID), developmental delay (DD), and epilepsy predominantly, is caused by a heterozygous mutation in the SYNGAP1 gene. SYNGAP1 mutations have been rarely reported in the Chinese population. Here, we present an investigation of SYNGAP1 mutations in a clinical cohort with ID and DD in Shandong, a northern province in China, to further explore the genotype and phenotype correlations. Methods: A retrospective study was conducted on 10 children with SYNGAP1 mutations presenting ID, DD, and epilepsy who were diagnosed between January 2014 and May 2022. Clinical data and genetic tests were collected. Treatment and regular follow-ups were carried out to pay close attention to the prognosis of the patients. Results: We described 10 unrelated affected individuals with SYNGAP1 mutations, displaying ID, DD, epilepsy, or seizures. All mutations of SYNGAP1 in the 10 patients were de novo, except patient 3 whose father was unavailable, including five nonsense mutations, two frameshift mutations, two splicing mutations, and one codon deletion. Among these mutations, five were novel and the other five were previously reported. Significantly, all patients with epilepsy were sensitive to anti-seizure drugs, especially sodium valproate. Furthermore, rehabilitation training seemed to exert a more improved effect on motor development than language development for the patients. Conclusion The 10 patients carrying SYNGAP1 mutations were diagnosed as MRD5. Five novel genetic mutations were found, which expanded the mutational spectrum of the SYNGAP1 gene. The identification of these mutations in this study helps explore the relationship between genotypes and phenotypes and contributes to genetic counseling and therapeutic intervention for patients with MRD5.

Keywords: SYNGAP1; autosomal dominant mental retardation type 5; developmental delay; epilepsy; intellectual disability; mutation; next-generation sequencing.